

Sponsored By:



Clinical Evaluation of VX-765 in Subjects with Partial Onset Seizures

James Paskavitz, M.D.

Vertex Pharmaceuticals, Incorporated

There is scientific evidence to support the idea that localized brain inflammation may contribute to refractory epilepsy. VX-765 inhibits pro-inflammatory cytokines and suppresses seizures in preclinical models of epilepsy.

A double-blind, placebo-controlled safety study was undertaken in subjects with treatment refractory partial onset epilepsy. 60 subjects were enrolled in the study. Adverse event profile was consistent with earlier clinical studies of VX-765. Though not statistically significant, trends of improvement were observed in the VX-765 treatment group.

VX-765 Study Team